Sunesis Pharmaceuticals News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Sunesis Pharmaceuticals Inc. lost $4.9 million in the September quarter. The South San Francisco business lost $7.1 million in the same quarter, its third, a year earlier.

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia .

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 31 Oct 2009 - 1:00 PDT Sunesis Pharmaceuticals, Inc.

The hallways at the recent BioPharm America conference in San Francisco were filled with biotech CEOs swapping war stories about how their companies almost - but not quite - bit the dust a few months ago.

Sunesis Pharmaceuticals, Inc. reported today that it received a letter, dated September 16, 2009, from the Listing Qualifications Staff of The NASDAQ Stock Market notifying Sunesis that it does not comply with the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550 .

New Enterprise Associates , which invested $2.3 million in Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec for the selection of a Raf kinase inhibitor development candidate for the ...

Sunesis Pharmaceuticals Inc. reported a first quarter loss of $8.4 million, or 24 cents a share, narrowed from a loss in the same period last year of $9.6 million, or 28 cents a share.